BNTX logo

BioNTech SE

BNTX
Healthcare|Biotechnology|DE
$87.51
+1.65 (+1.92%)
DCF Value
$46.34
Tangible Book / Share
$64.71
Cash / Share
$58.79

About

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.

Stock Price

-15.3%(1Y)
1M
-4.9%
3M
-6.6%
6M
-7.0%
YTD
-8.1%
1Y
-16.7%
3Y
-12.2%
5Y
-63.9%

Pipeline Summary

141 total trials
78
Phase 1
77
Phase 2
30
Phase 3
2
Phase 4
Completed: 50Active: 25Terminated: 17Unknown: 6Recruiting: 36Withdrawn: 3Not Yet Recruiting: 4

Active Trials (61)

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222Locally Advanced Breast Cancer
Phase 2Active
Enrollment: 83 participants
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
NCT05879068SCLC
Phase 2Active
Enrollment: 99 participants
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05150691HER2-positive Advanced Solid Tumor
Phase 1Phase 2Recruiting
Enrollment: 796 participants
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
NCT07730450COVID-19 Vaccines
Phase 4Recruiting
Enrollment: 200 participants
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
NCT07843940Extensive-stage Small Cell Lung Carcinoma
Phase 1Phase 2Recruiting
Enrollment: 55 participants

BioScore

5.4/10
Watchlist

Key Facts

Market Cap$21.70B
Employees7,807
CEOUgur Sahin
IPO DateOct 10, 2019
Beta1.29
52-Week Range$79.52 – $124
Avg Volume1,142,597
ExchangeNASDAQ

Ownership

Float99.6%
Shares Outstanding247.9M

Recent Insider Trades

Sahin UgurSELL
Oct 8, 202627,000 shares @ $92.31
Sahin UgurSELL
Oct 9, 202636,209 shares @ $95.37
Sahin UgurSELL
Oct 7, 202624,000 shares @ $95.86
Sahin UgurSELL
Oct 5, 202672,000 shares @ $97.23
Sahin UgurSELL
Oct 6, 202621,000 shares @ $96.81

Peers

CGENCompugen Ltd.
$185.7M
GMABGenmab A/S
$32.98B
IBRXImmunityBio, Inc.
$9.15B
IMCRImmunocore Holdings plc
$1.60B
IMTXImmatics N.V.
$951.7M
INCYIncyte Corporation
$24.39B
IOVAIovance Biotherapeutics, Inc.
$3.64B
MGNXMacroGenics, Inc.
$148.4M
Data last updated: Nov 9, 2026, 04:00 AM